Bosulif treatment for adults with chronic myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, post‑marketing program collecting safety and effectiveness information on bosulif when prescribed in routine clinical practice. Eligible adults are those who are being treated with bosulif or who will begin bosulif treatment according to local product labeling, including patients who started within one year before consent. Data are collected during normal clinic visits with informed consent, and patients contraindicated for bosulif or who refuse use of their data are excluded. The study is sponsored by Pfizer and aims to describe real‑world outcomes rather than change assigned treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who are being treated\* or will be treated with Bosulif according to it's local product document under routine clinical practice (\*Patients who initiated Bosulif treatment within one year before consent)
2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

\- Patients to whom bosulif is contraindicated as per the local labeling- Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information

Where it's running

• Pfizer New York
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asciminib for children and teens with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

  This study will try asciminib as a treatment for children aged 1 to under 18 with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase, including newly diagnosed patients and those who are resistant or intolerant to prior TKIs, with or without the T315I mutation.

  Recruiting at 39 sites Phase 2 Novartis · Chicago, Illinois and 38 other locations · NCT07354074

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Evaluating TGRX-678 for patients with advanced Chronic Myelogenous Leukemia

  This study is testing a new drug called TGRX-678 to see if it can help people with advanced Chronic Myelogenous Leukemia who haven't had success with other treatments.

  Recruiting at 2 sites Phase 1 Shenzhen TargetRx Co., Ltd. · Houston, Texas and 1 other locations · NCT06088888

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Long-term safety treatment for chronic myelogenous leukemia patients

  This study is testing the long-term safety of a medication called asciminib for patients with chronic myelogenous leukemia who have already been part of another study.

  Recruiting at 61 sites Phase 4 Novartis · Ann Arbor, Michigan and 87 other locations · NCT04877522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.